Place of drugs acting on metabolism in primary health care in the prevention and treatment of ischemic syndromes
Coronary artery disease is a leading cause of death in cardiovascular mortality. Studies conducted over the past decades helped to understand the specific pathophysiological processes occuring in cardiomyocytes during ischemia, to identify new clinical syndromes of ischemia and evaluate the cytoprotective role of therapy in combination treatment of coronary artery disease. Trimetazidine is one of the most studied drugs in cytoprotective treatment. High efficacy and good tolerability qualify it as the best way to protect cardiomyocytes in stable angina.